RLX Technology Inc. (RLX) Earnings Call Transcript & Summary

September 21, 2022

New York Stock Exchange US Consumer Staples Tobacco earnings

Earnings Call Speaker Segments

Sam Tsang

executive
#1

Thanks so much. Greetings, everybody, and I’m glad to have you join us for RLX Technologies’ earnings conference call covering the second quarter of 2022. Earlier today, the firm’s operational and financial outcomes went out via PR newswire services and were posted on the internet. You may also read the earnings press release if you go to the IR area of our site, ir.relxtech.com. Joining us on this call are our CEO, Ms. Kate Wang; our CFO, Mr. Chao Lu; and me, Sam Tsang. Prior to proceeding, kindly be aware that remarks today will include forward-looking statements issued pursuant to the Safe Harbor clauses of the U.S. Private Securities Litigation Reform Act of 1995. Such statements generally feature terms like may, will, expect, target, estimate, intend, believe, potential, continue, or comparable wording. Forward-looking statements carry inherent risk and uncertainties. A variety of business risks and uncertainties might affect how accurate these statements turn out to be, and those factors could lead actual results to diverge materially from what was projected or anticipated, with many such factors lying outside our control. Neither the company nor its affiliates, advisors, or representatives accept any duty to refresh this forward-looking information unless applicable law demands it. Please be advised that RLX Technology’s earnings press release and this conference call both cover unaudited GAAP financial measures and unaudited non-GAAP financial measures. Within RLX’s press release, you’ll find a reconciliation linking the unaudited non-GAAP measures to the unaudited GAAP measures. At this point I’ll hand the call to Kate. Please go ahead.

Kate Wang

executive
#2

Thank you, Sam, and I appreciate everyone taking the time to be with us on today's earnings conference call. I feel good about the solid financial results we posted for the second quarter, during which we kept proactively adjusting to the new regulatory framework. Our focus stays on improving every part of what we can do, spanning scientific research, product development, manufacturing advancements and operation optimization, and all of that allowed us to steer through highly dynamic markets and a shifting regulatory landscape. Despite strong macro headwinds and weak consumer sentiment, our strong second quarter results highlighted how resilient our defensive business model is and how dedicated we are to building and strengthening our brand's trustworthiness. There's growing attention being paid to how businesses are updating their operations. I'd like to open with a brief look back at some notable regulatory milestones that have shaped our sector. Beginning in Q1 of 2022, government bodies in China rolled out a set of implementation rules along with guiding opinions aimed at tightening supervision over e-cigarette products and bringing order to the e-cigarette industry. Those include the administrative measures governing e-cigarettes, which take effect in May, plus the new national standard scheduled to go into force on October 1, 2022. With that context, I'll now walk you through where we stand on the license applications we've filed under the requirements set by the administration measures. As of today, two of the companies we own have been granted a manufacturing enterprise license by the State Tobacco Monopoly Administration, STMA, allowing them to carry out manufacturing operations while following regulatory oversight. To be specific, one of them has received approval to produce e-liquids, while the other has been approved to hold the RELX brand and to make RELX branded e-vapor rechargeable devices, cartridge products and other related items. Getting these licenses marked an important step forward in our strategic roadmap, because we are proactively adopting this new paradigm by complying with regulations without delay. We are confident that our strong fundamentals, our research and development capabilities that lead the industry, and our experienced teams will continue to support our mission of reaching full regulatory compliance across our operations on the timeline we have set. To keep that momentum going, we've intensified our push to create offerings that satisfy the relevant regulatory criteria while also meeting what customers want. A number of our recent launches ranked among the earliest statured items in the sector to secure sign-off under the updated national standards — strong proof of how far ahead our R&D strength stands. We're eager to get that cleared item into the market < >, and we're sure its quality, performance and safety will keep winning over our customers. Right now, multiple other freshly engineered items sit in technical review, and plenty more are queued up in the application process. Looking ahead, we'll stay dedicated to meeting what our users need — safe, high-quality items — while following regulations closely and seeking out fresh avenues for growth within the industry. Specifically, we have strong conviction that research and development is essential to both our achievements and our ability to grow sustainably going forward. Thanks to R&D, we've been able to bring compliant new offerings to market quickly and keep our brand ahead of competitors. Let me now go through a few metrics we rely on to track our investment in R&D. In 2018, R&D expenses on a non-GAAP basis represented 1.5% of our ratio, and that number had grown to 3.6% by the first half of 2022; going forward, we expect it to continue increasing across the coming years. Apart from product R&D, we also put real effort into basic scientific work aimed at safeguarding our users' health, striving constantly to gain a deeper understanding of — and reduce — the health dangers tied to < > e-vapor products. To that end, besides exploring within our own scientific labs, we've teamed up with a range of prominent research organizations — among them ten universities, two hospitals, and multiple independent academic research houses — to carry out the relevant R&D, which lays a solid groundwork for continuous product development and innovation. Also in Q2, we partnered with the Shenzhen Institutes of Advanced Technology and the Chinese Academy of Sciences to research how cooling agents are inhaled through e-vapor; what they discovered is that products containing WS-23 generate less of a rewarding effect than those with nicotine alone — we view this as a major step forward that can help us deliver a superior and safer experience to adult smokers. Turning now to operations: while continuing to meet all applicable regulatory requirements, we spent the second quarter further streamlining our corporate structure and the way we run day-to-day processes, which makes us nimbler and more adaptable. Early results from this approach are promising — our non-GAAP expense ratio declined from the prior quarter. Chao will go into greater detail about that in a moment. We have no doubt that this broad operational enhancement will position us to manage major transitions effectively and pivot rapidly as market conditions change. Our near-term and long-term mutation fees are guided by both teams. In closing, our belief in the inherent promise of China's e-vapor sector remains firm. As a dependable e-vapor brand serving adult smokers, we are confident that our industry-leading technologies and scientific progress, premium user base, adaptable business model, and robust execution across our core assets will enable us to achieve lasting, quality-driven expansion over time while strengthening our standing as a leader in the industry. Beyond that, what matters most is that we continue seeking the clearances regulators require, ensuring all applicable obligations are satisfied on time. At the same time, we'll build products that meet qualification standards and perform at a high level, push operational efficiency even higher, and capture the growth chances this industry will present going forward. That said, I'll now pass things to Chao Lu, our CFO. He will walk everyone through several of the initiatives from the quarter just ended and provide a closer look at how we performed operationally and financially. Chao, the floor is yours.

Chao Lu

executive
#3

Thanks, Kate, and greetings, everyone. I'd like to give you a summary overview of how we performed financially in Q2 2022. Against the backdrop of a tough macro setting and a COVID resurgence, consumer sentiment dropped to an all-time low during the second quarter. As reported by the National Bureau of Statistics of China, the overall consumer confidence index declined from 121.5% in January 2022 to 88.9% in June 2022; in addition, total retail sales across China fell 0.7% year-over-year during the first half of 2022; we are actively adjusting our business to the market and working hard to enhance our operational efficiency, and we turned in solid and healthy results for the second quarter, posting net revenue of RMB2.2 billion; that said, we think this elevated revenue level in Q2 stemmed mostly from front-loading of sales within the downstream value chain ahead of the discontinuation of our older products, as the industry transition period approaches its conclusion in the third quarter. Revenue was down year-over-year; that decline, though, was chiefly attributable to the expansion of store expansion and new product launches throughout the regulatory transition period, as we strive to strictly comply with the relevant requirements. Gross profit came to roughly RMB1 billion in Q2, with a gross margin of 43.8% for the second quarter, versus 45.1% in the comparable quarter of 2021. The gross margin decline resulted mainly from an unfavorable product mix shift, a rise in inventory provision, and an impairment loss recognized for PP&E in order to comply with recent regulatory development. Because share-based compensation expenses rose significantly, to RMB193.2 million from a positive RMB172.5 million in last year's same quarter, our operating expenses hit RMB530.9 million in Q2 2022, against RMB176.2 million — sorry, RMB167.2 million in last year's comparable period. More specifically, our selling expenses dropped 2.7% to RMB122.6 million in Q2 2022 from RMB126 million in the comparable period of 2021, primarily driven by a reduction in salaries, welfare benefits and branding material expenses, though partly offset by a rise in share-based compensation expenses. General and administrative expenses grew to RMB290.7 million in Q2 2022 from RMB46.1 million in the same quarter of 2021, mainly driven by increases in share-based compensation, salaries and welfare benefits. Since we remain focused on strengthening our R&D capabilities, our research and development expenses came to RMB117.6 million in Q2 2022, versus a positive RMB4.9 million in the comparable period of 2021. That increase was mainly driven by rises in share-based compensation expenses, salaries and welfare benefits and consulting expenses. To echo what Kate said regarding our business structure enhancements, our proactive cost optimization initiatives also continue to pay off this quarter. Excluding share-based compensation, our non-GAAP expense ratio declined to 15.1% in the second quarter from 20.9% in the prior quarter. In particular, our non-GAAP selling expense ratio fell to 4.7% during Q2, down from 6.9% in the quarter before. When one-off items like impairment loss are taken out, our adjusted expense ratio came in around the same level as the equivalent period a year earlier; in our view, those adjusted figures might do a better job of showing what we accomplished and the progress we made on operational improvement in the quarter. Consequently, non-GAAP net income rose to RMB634.7 million, up from RMB351.8 million in the previous quarter. For Q2 2022, non-GAAP basic net income per ADS came to RMB0.494, while the diluted figure was RMB0.492. Turning to the balance sheet, ours is a solid one. Our cash position in particular stays strong: cash and cash equivalents, restricted cash, short-term bank deposits, short-term investments and long-term bank deposits, net, totaled RMB16.8 billion at the close of June 2022, versus RMB14.9 billion 12 months earlier. Beyond that, we brought in positive cash — operating cash flow of RMB1.4 billion, and the ratio of operating cash flow to non-GAAP net income climbed to 228% in Q2 2022, up from 100% during the comparable period a year prior. Thanks to our strong cash position and ample operating cash flow, cash inflow, we could adjust our business nimbly amid challenges and back our push to seize possible growth opportunities in the industry; given the regulatory changes, we have made a slow but steady beginning on sales of our new products, which comply with the national standards, via the new transaction system the regulator requires. To wrap up, we think e-vapor products will keep serving an essential role in harm reduction for adult smokers as the industry enters this new regulatory era. Thanks to the superior quality and safety of our products, our brand will keep connecting strongly with adult smokers. Going forward, our attention will be on cost optimization as we keep strengthening how competitive our products are, so as to deliver sustainable long-term growth for shareholders. That wraps up our prepared remarks today. We will now open the call to questions. Operator, please go ahead.

Lydia Ling

analyst
#4

Hello, everyone. I appreciate it, management, and this is Lydia calling in from Citibank, and thank you as well for the presentation. So, I've got three questions here, and the first one is that we've actually begun — a number of the new items have been rolled out in certain regions. So we'd like to hear what feedback users have given so far, and also, with the transition period and just a few days in, what kind of effect do you expect your new flavors to have on sales volume over the coming quarters? That's question one. Then question two: we noticed that a few of your retailers might now be carrying more than three brands at the store level. So we'd like your perspective on how competition will shape up going forward. And the final question — well, it's September now. So could you walk us through how the third quarter is tracking so far, plus what you see ahead for the fourth quarter and for 2023? Thank you.

Chao Lu

executive
#5

Many thanks, Lydia. So, the initial question deals mostly with sales volume at 43%, the next one deals mostly with how the competitive landscape is developing, and the last one concerns the outlook for the third quarter and beyond. As for the first, it's about what the impact will be once we roll out products meeting the national standards, since we only brought these out a few weeks back. Honestly speaking, I'd say the overwhelming majority of our user base hasn't yet had an opportunity to sample what we offer. And since we remain within the transition window, running through September 30, it's hard for us to offer quantitative guidance on upcoming quarters, because certain products are still going through approval right now. However, if we consider the lessons and figures drawn from the < > pattern seen in the United States during 2020, several quarters passed before users there in the U.S. When it comes to markets adjusting to the new flavors, we did cover the industry volume. As a result, over the past few weeks, a growing number of products have received approval, and our belief is that these could hit the market very soon and serve the needs of more of our existing users. So once users have had time to digest the flavor and work through inventories on hand, we'll get a clearer read on how our user demand is shifting, and that will come late in 4Q. On your second question about the possibility of multiple brands being sold in a single store going forward, our take is that what retailers ultimately want is to maximize productivity at their stores and their own profitability. When it comes to carrying just one brand per store, under the new regime retailers are required to sell multiple brands. We don't anticipate any material effects on the competitive landscape, since retailers have always had the option of picking which recommended brand to work with. In our view, then, product quality, brand equity, and user base ought to determine a brand's share of the store. Based on what we've observed, our brand share has stayed steady over the past few months. Looking ahead, we'll keep putting investment into strengthening our R&D capabilities, and our non-GAAP R&D expense has been rising steadily across the past quarters, with further growth expected in the quarters to come. Thanks to these greater R&D efforts, we'll keep delivering a better and safer experience for adult smokers. Your last question concerns the fourth quarter outlook. As we laid out in our opening remarks, our second quarter revenue got a boost from front-loading of sales in the downstream value chain, as players anticipated the discontinuation of our older products with the industry transition period approaching its end in the third quarter. That elevated comparison base will weigh on our sequential third quarter results. At the same time, we steadily reduced shipments of old products across the third quarter in order to better carry into the new regime, and that will affect our first quarter numbers. So since the transition period is set to conclude on the September 30, we'll need more time before we can better project the future outlook, particularly for the fourth quarter. Thank you for your questions.

Lydia Ling

analyst
#6

Thanks.

Charlie Chen

analyst
#7

Thanks to the management team for fielding my questions. There are 2 things I'd like to ask about. The first concerns your product pipeline, particularly the new offerings, which ought to comply with the fresh regulations or the new national standard; so what I'd like to find out is, where do things stand with your new product application? Specifically, what's the count that has been approved? What's the count still pending, and also what's the count that has been rejected, if any exist? And what's your product portfolio plan for the year ahead, roughly the next 12 months? So that's my first question. Next, I'd like to ask about the timeline for cycling out or, rather, reworking your product lineup. From what I remember, during the previous call you mentioned intentions to retire legacy items sometime in Q2 or Q3. What I'm after is the exact moment when you stopped making or discontinued the older goods that fail to meet the national — the updated national standard; plus the timing of when newly developed items kicked off manufacturing or first went on sale in the markets. That covers both of my inquiries.

Chao Lu

executive
#8

Appreciate that, Charlie; the initial item deals mostly with product approvals, while the subsequent one relates to how the older products performed. Basically, with the new rules in place, any fresh item must get the green light before it hits the market, and that application procedure will be something we keep working on continuously. As a result, we'll continue broadening what we offer under this updated framework and deliver high-quality items for grown-up smokers. Right now, we've gotten the green light on a low-teens number of devices along with a low-teens number of cardio items, while some of our submissions are still being looked at, and we expect the total of cleared products to keep rising. On the second point, regarding the winding down of older products, we intentionally reduced how fast we were manufacturing as the third quarter went on, with the bulk of output happening during the first half of Q3. As for products meeting national standards, this month we started taking part in trials for a transition platform. Over the last several weeks, the number of green lights we've gotten has gone up, which means we're only at the beginning when it comes to getting these newly launched items out to the market. Because customers can still use what we offered before, and because clearance for these new items came through only a short time ago, the revenue we're currently seeing from them might not give a true picture of actual usage needs. As a result, once this switchover window has passed, we'll be in a position to share further details. Thanks.

Charlie Chen

analyst
#9

Thank you.

Peihang Lyu

analyst
#10

Hello, management. Peihang here from CICC, and I appreciate the chance to ask my questions. Actually, I have 3 questions; the first is, could you briefly walk us through where inventory levels stand right now for your original projects, and should we expect any additional impairment on that inventory? My second question is, I'd like to understand what recent changes you've made now that stores can't be run if they're shut? And the last one is, given that the national e-cigarette online trading platform has now launched, I'd like to hear about your most recent progress when it comes to working with the tobacco administration and other indices? Thank you.

Chao Lu

executive
#11

Thank you, Peihang. So the first item is about how much stock we're carrying and the way we account for write-downs on that stock. The second item has to do with the exclusive arrangements that were previously in place with the people who run our stores. And the final item relates to the latest progress on the platform we're using for the transition. Turning to stock levels for our new products and the write-downs they may require: sales of new products that meet national standards got underway gradually but steadily, and on top of that, our users are going to need more time before they've worked through the older inventory and changed their habits as users. As a result, the amount of stock we're holding for new products is fairly small compared with what we were carrying for the older series before the transition period began. On the inventory side, since the fourth quarter of 2021 we've been booking regular provisions against both product that fails to meet the new national standards and raw materials that can no longer be used. Looking ahead to the coming quarters, we don't expect to take any more sizable inventory provisions related to product that does meet those national standards. The second question has to do with the exclusivity arrangements we used to have with our store owners. Once the STMA issued its rule in March 2022 saying branded stores can't have exclusive distribution agreements, we began ending those agreements with store owners and giving back their deposits. By the time we wrapped up the second quarter, the bulk of that effort was already behind us. From where we sit, losing exclusivity opens the door for us — it lets us pursue sourcing work that in the past only other brands could take on. Looking ahead, I believe retailers will still gravitate toward brands that carry strong equity and occupy real space in users' minds, and that those products will in turn help retailers get more out of their stores. From what we've seen ourselves, a lot more store owners began carrying x branded products once exclusivity ended. And the last item has to do with how our trading platform process works — as of the beginning of this month, multiple regions nationwide started moving onto the National transition platform. Being a top player in China's e-cigarette sector, we felt glad that we made the cut as one of the initial handful of labels invited to take part. Our progress through this transition has been trouble-free, and we're grateful for all the backing the STMA has given us. Take this as an illustration: members of our staff have gone through training programs organized by research bodies, quality oversight groups, and entities handling testing criteria, along with technical help provided via our work with the STMA on the national standards. Thanks to that backing and assistance, the goods we brought out most recently landed in the first batch of offerings in our field to gain clearance after the fresh rules kicked in. I'm grateful.

Peihang Lyu

analyst
#12

Got it, that's quite clear. Thanks a lot.

Sam Tsang

executive
#13

Thanks again for being with us today. Should you have any more questions, don't hesitate to reach out to the Investor Relations team at RLX Technologies using the contact details listed on our website, or get in touch with TPG Investor Relations.

Operator

operator
#14

This concludes this conference call. You may now disconnect your line. Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete RLX Technology Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to RLX Technology Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in RLX Technology Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.